In development
A new acoustic-wave modality for professional hair restoration.
Folliwave is developing Sonogrow, an in-clinic platform that uses acoustic-wave technology to activate mechanotransduction-based biological pathways.
For investor, clinical and strategic-partner conversations.
Established foundation. Focused execution.
Built on substantial technology heritage, with focused execution ahead.
Folliwave is being formed as a focused spin-off from an established medical-device technology platform, combining acoustic-wave know-how with a dedicated product, proprietary IP, regulatory strategy and evidence program.
Acoustic-wave foundation
A mature energy form supported by decades of medical-device development experience.
Distinct modality
Mechanotransduction engages biological pathways beyond pharmaceutical mechanisms.
Clinic-first model
Designed around practical workflows, seamless clinic integration and sustainable professional economics.
A focused mechanical stimulus is delivered to the treatment area.
Physical energy is translated into cellular signaling.
Pathways associated with microcirculation and follicle support.
Value hierarchy
Standalone value first. Protocol compatibility by design.
Sonogrow is being developed to deliver meaningful clinical and commercial value as its own professional modality. As hair restoration continues to move toward combination care, its non-pharmaceutical mechanism is also designed to fit naturally alongside existing clinic protocols.
Current stage
Launching a limited Founding Partner Program.
Folliwave is selectively recruiting leading hair-restoration clinics to join the program and receive priority access.
Leadership
Experienced across medical devices, aesthetics and clinical hair restoration.
Coming soon
Let’s talk about the future of professional hair restoration.
Folliwave is currently engaging investors, clinical leaders and strategic partners.
shachar.a@folliwave.com